AlphaRET

AlphaRET is a clinical-stage biopharmaceutical company focused on developing sustained-release therapies for chronic retinal diseases. The company's lead product candidate, AL-001, is a bioerodible intravitreal implant that delivers brimonidine, an alpha-2 adrenergic receptor agonist, over an extended period of several months. This technology is designed to provide neuroprotection and reduce the progression of conditions such as diabetic retinopathy and geographic atrophy associated with age-related macular degeneration. By utilizing a long-acting delivery system, AlphaRET aims to significantly reduce the treatment burden associated with frequent ocular injections. The company was founded by prominent retina specialists and is headquartered in Laguna Hills, California.